Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

313.97
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
244.28
Today|||52-Week Range
348.84
+20.20%
Year-to-Date
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
Nov 17 / Zacks.com - Paid Partner Content
Lockheed Martin leads biggest decliners on S&P 500
Oct 24 / FT.com - Paid Partner Content
Celgene sales target cuts signal wider biotech blues
Oct 26 / FT.com - Paid Partner Content
 

Today’s Trading

Previous close313.97
Today’s open313.47
Day’s range310.18 - 316.00
Volume907,441
Average volume (3 months)1,324,228
Market cap$66.4B
Dividend yield--
Data as of 4:00pm ET, 11/17/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+9.20%
Earnings growth (next 5 years)+6.00%
Revenue growth (last year)+9.37%
P/E ratio19.3
Price/Sales6.09
Price/Book5.58

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc0.000.00%
GILDGilead Sciences0.000.00%
----
BIVVBioverativ Inc0.000.00%
Data as of 4:00pm ET, 11/17/2017

Financials

Next reporting dateJanuary 31, 2018
EPS forecast (this quarter)$5.59
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Senior Vice President-
US Therapeutic Operations
Alisha A. Alaimo
Corporate headquarters
Cambridge, Massachusetts

Forecasts